ANI Guidance Raise Can’t Stop Stock Price Slump
Another Strong Quarter For ANI Was Overshadowed By Panic Among Investors
Stock prices at ANI Pharmaceuticals dropped 14.8% following its Q3 results announcement, despite a guidance raise from the company, after it noted that competitor supply disruptions seemed to be easing off.
